Is a complete GANX research report available?

No complete published report is available for Gain Therapeutics, Inc. (GANX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · USD

$1.76

+0.07 (+4.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first GANX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	75.1M
Net income (ttm)	-21.2M
EPS (ttm)	-$0.58
Shares out	42.7M
Volume	696,126
Beta	0.16
Price target	$7.20	+309.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -21.2M
EPS (ttm): -$0.58
Market cap: 75.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GANX indicators

Market & fundamental data

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001819411
Company name	Gain Therapeutics, Inc.
Country	United States
Country code	US
Cusip	36269B105
Employees	21
Employees Change	-4%
Employees Change Percent	-16
Enterprise value	$55.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-03-18
Isin	US36269B1052
Last refreshed	2026-07-31
Market cap	$75.1M
Market cap category	Micro-Cap
Price	$1.76
Price currency	USD
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	GANX
Website	https://gaintherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-29.73%
FCF yield	-27.11%
P/B ratio	5.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-10.6M
Net Income	$-21.2M
Net Income Growth Years	2%
Profit Per Employee	$-1M
ROA	-81.15
Roa5y	-57.16
ROCE	-132.6
ROE	-214.7
Roe5y	-127.1
ROIC	-117

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	12.11%
Cagr3y	-23.23%
Cagr5y	-26.49%
EPS Growth Quarters	1
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$18.7M
Cash	$16.5M
Current Assets	$18.2M
Current Liabilities	$3.9M
Debt	$672,302
Debt Equity	$0.05
Equity	$14M
Liabilities	$4.7M
Long Term Assets	$516,696
Long Term Liabilities	$844,913
Net Cash	$15.9M
Net Cash By Market Cap	$22.21
Net Cash Growth	87.48%
Net Debt Equity	$-1.13
Tangible Book Value	$13.9M
Tangible Book Value Per Share	$0.33
WACC	5.06

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.69
Net Working Capital	$-2M
Quick ratio	4.51
Working Capital	$14.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-42.24%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	12.1%
200-day SMA	2.2
3Y total return	-54.76%
50-day SMA	1.78
50-day SMA vs 200-day SMA	50under200
5Y total return	-78.54%
All Time High	17.93
All Time High Change	-90.18%
All Time High Date	2021-04-12
All Time Low	0.89
All Time Low Change	97.75%
All Time Low Date	2024-08-13
ATR	0.12
Beta	0.16
Beta1y	2.14
Beta2y	2.08
Ch YTD	-45.34
High	1.79
High52	4.34
High52 Date	2025-12-11
High52ch	-59.45%
Low	1.66
Low52	1.41
Low52 Date	2025-08-01
Low52ch	24.82%
Ma50ch	-1.35%
Premarket Change Percent	6.51
Premarket Price	$1.8
Price vs 200-day SMA	-19.85%
RSI	49.03
RSI Monthly	43.38
RSI Weekly	45.54
Sharpe ratio	0.64x
Sortino ratio	1.02
Total Return	-42.24%
Tr YTD	-45.34
Tr1m	-11.11%
Tr1w	-3.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	2
Analyst Price Target Top	$6.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.15
Operating Income	$-19.7M
Price target	$7.2
Price Target Change	$309
Price Target Change Top	$269

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,645,311%
Float Percent	97.64%
Net Borrowing	-99,784
Shares Insiders	2.36%
Shares Institutions	19.67%
Shares Out	42,654,038
Shares Qo Q	11.66%
Shares Yo Y	42.24%
Short Float	8.62%
Short Ratio	2.56
Short Shares	8.41

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-21.2M
Adjusted OCF	-21,158,632
Average Volume	640,803.45x
Bv Per Share	0.33
Ch1m	-11.11
Ch1w	-3.3
Ch1y	12.1
Ch3y	-54.76
Ch5y	-78.54
Ch6m	-8.33
Change	4.14%
Change From Open	3.53
Close	1.69
Days Gap	0.59
Depreciation Amortization	44,689
Dollar Volume	1,225,181.8
Earnings Date	2026-08-10
Earnings Time	bmo
EBIT	$-19.7M
EBITDA	$-19.6M
EPS	$-0.58
F Score	3
FCF	$-19.4M
FCF EV Yield	-34.85x
FCF Per Share	$-0.45
Financing CF	26,455,009
Fiscal Year End	December
Founded	2,017
Income Tax	$943,675
Ipr	-84.77
Iprfo	-85.07
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-11
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	2.02
Ma150ch	-12.96%
Ma20	1.77
Ma20ch	-0.4%
Net CF	7,472,663
Next Earnings Date	2026-08-11
Open	1.7
Optionable	Yes
Position In Range	76.92
Post Close	1.76
Postmarket Change Percent	-2.33
Postmarket Price	$1.72
Ppne	355,011
Pre Close	1.69
Price Date	2026-07-30
Ptbv Ratio	5.13
Relative Volume	1.09x
Share Based Comp	1,787,200
Tr6m	-8.33%
Us State	Maryland
Volume	696,126

Gain Therapeutics, Inc. (GANX)

Coverage state: Market snapshot only — no published research

Generate the first GANX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · GANX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GANX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GANX

Frequently asked questions